Compare Royal Bank of Canada (RY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Bank of Canada vs Vertex Pharmaceuticals Incorporated — how do they compare? Royal Bank of Canada trades at $210.37 (market cap $289.51B), while Vertex Pharmaceuticals Incorporated trades at $481.47 (market cap $121.95B). The key difference: Royal Bank of Canada is far larger — about 2.4× Vertex Pharmaceuticals Incorporated's market cap, and Royal Bank of Canada pays a 2.42% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| RY | VRTX | |
|---|---|---|
Market Cap | $289.51B | $121.95B |
Sector | Financials | Health |
52-Week High | $217.87 | $529.59 |
52-Week Low | $128.46 | $366.54 |
Dividend Yield | 2.42% | — |
Enterprise Value | — | $116.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Bank of Canada (RY) trades at $210.37, down 2.35% today, with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows bullish technical signals with moving averages supporting upward momentum, though RSI levels suggest potential overbought conditions. Recent financial performance includes robust revenue growth to $66.53B in 2025 and a healthy net income margin of 31.85%, while the company maintains a solid dividend program with recent increases.
RY presents a mixed outlook with strong fundamentals and analyst support but faces valuation concerns. The company's consistent earnings beats and shareholder returns through dividends and buybacks provide upside potential, though elevated P/E and P/S ratios warrant caution. Key risks include economic sensitivity and competitive pressures in the banking sector.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
